Susquehanna International Group
PSTX

Susquehanna International Group’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Susquehanna International Group’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-42,700
Closed -$410K – 13801
2024
Q4 		$410K Sell
42,700
-81,200
-66% -$424K ﹤0.01% 9152
2024
Q3 		$354K Sell
123,900
-158,000
-56% -$489K ﹤0.01% 9245
2024
Q2 		$823K Buy
281,900
+119,700
+74% +$327K ﹤0.01% 7054
2024
Q1 		$517K Buy
+162,200
New +$541K ﹤0.01% 8423
2023
Q4 		– Sell
-65,400
Closed -$156K – 13487
2023
Q3 		$156K Buy
65,400
+18,600
+40% +$39K ﹤0.01% 10511
2023
Q2 		$82.4K Buy
+46,800
New +$120K ﹤0.01% 11088
2023
Q1 		– Sell
-24,200
Closed -$128K – 13684
2022
Q4 		$128K Sell
24,200
-13,800
-36% -$63.1K ﹤0.01% 10690
2022
Q3 		$134K Buy
+38,000
New +$126K ﹤0.01% 11396
2021
Q3 		– Sell
-15,300
Closed -$153K – 13752
2021
Q2 		$153K Buy
+15,300
New +$137K ﹤0.01% 11841

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna International Group's PSTX Position: Q1 2025 in Review

Susquehanna International Group sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 198,375 shares — an estimated $1.9M sold.

Susquehanna International Group first reported a position in PSTX in Q1 2021 and held it in 11 quarters. The position peaked at $2.01M in Q1 2023. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • Susquehanna International Group reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 198,375 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $1.9M.
  • Susquehanna International Group first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2021 and held it in 11 quarters.
  • Susquehanna International Group's Poseida Therapeutics, Inc. Common Stock position peaked at $2.01M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.